RecruitingNCT05354622

Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)

Investigating the Genetic Basis of Hereditary Spastic Paraplegia


Sponsor

Boston Children's Hospital

Enrollment

200 participants

Start Date

Apr 25, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide. In childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice. In this study, the investigators hope to identify genetic factors related to HSP. By identifying different genetic factors, the investigators hope that over time we can develop better treatments for sub-categories of HSP based on cause.


Eligibility

Min Age: 1 MonthMax Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with hereditary spastic paraplegia, motor neuron disease, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Boston Children's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05354622


Related Trials